ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 11 of 39
УЖМБС 2021, 6(2): 77–86
Clinical Medicine

Adiponutrin as a Marker of Metabolic Disorders in Patients with Hypertension with Overweight and Obesity

Kravchun P. G., Kadykova O. I., Herasymchuk U. S.

Hypertension is a leading risk factor for coronary heart disease, stroke, peripheral arterial disease, kidney disease, vascular cognitive impairment, and mortality worldwide. Obesity in combination with hypertension continues to attract considerable attention from scientists. Despite the presence of experimental and clinical evidence of mutual burdening of hypertension and obesity, the mechanisms of formation of pathophysiological consequences of such a combination remain insufficiently defined. That is why in recent years an important role is given to the adiponutrin protein. The purpose of the study is to assess the nature of the relationship between adiponutrin levels and lipid and carbohydrate metabolism depending on the duration and degree of hypertension and the degree of obesity in patients with this comorbid pathology. Material and methods. The study included 107 patients with hypertension who were hospitalized in the cardiology department of Municipal noncommercial enterprise "Kharkiv City Clinical Hospital No.27" of Kharkiv municipal council. The age of patients ranged from 32 to 79 years (mean age was 58.6±9.88), who had not previously received regular antihypertensive therapy. The control group consisted of 20 age- and sex-appropriate healthy individuals. The level of adiponutrin was determined in 58 patients with hypertension of the 1st - 3rd degrees, aged from 32 to 79 years (mean age was 57.5±10.11 years), while hypertension of the 1st degree was diagnosed in 12 (20.7%) patients, hypertension of the 2nd degree - in 16 (27.6%), and hypertension of the 3rd degree - in 30 (51.7%) of the examined patients. Blood pressure was measured in patients in a sitting position after 5 minutes of rest, anthropometric measurements were performed, lipid profile and indicators of carbohydrate metabolism were evaluated, adiponutrin levels (pg/mL) were determined by enzyme immunoassay method using The RayBio® Adiponutrin Enzyme Immunoassay (EIA) Kit, (USA). Results and discussion. In all groups of patients with hypertension with overweight and obesity, adiponutrin levels were significantly elevated, and lipid and carbohydrate profiles tended to increase. Significant direct correlations were found between adiponutrine and triglycerides, with very low-density lipoprotein cholesterol of a moderate nature, and draws attention with a very high body mass index. In considering the differences in adiponutrin levels depending on gender, it was found that men have higher adiponutrin levels than women. Conclusion. Thus, we have the opportunity to consider adiponutrin as a marker of metabolic disorders

Keywords: adiponutrin, hypertension, obesity, carbohydrate metabolism, lipid metabolism

Full text: PDF (Ukr) 302K

  1. Arboix A. Hypertension and the acute phase of intracerebral haemorrhage: More evidence of the ‘silent killer’. Eur J Neurol. 2018 May; 25(8): 1007-8.
  2. Johnson MC, Banaag AL, Condie KJ, Servies TE, Koehlmoos TLP. New ACC/AHA Blood Pressure Guidelines and the Operational Readiness of Naval Aviators and Aircrew. Aerosp Med Hum Perform. 2019 Apr; 90(4): 409–14.
  3. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2018 Nov; 392(10159): 1923.
  4. Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. Obesity Management Task Force of the European Association for the Study of Obesity European Guidelines for Obesity Management in Adults. Obes Facts. 2015 Dec; 8(6): 402-24.
  5. Hauner H, Woodward E. Looking Back-EASO Is Celebrating Its 30th Anniversary. Obes Facts. 2016 Nov; 9(5): 363-4.
  6. WHO. World Health Organization. 2016. ProMED-mail website. Available from http://:
  7. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Reviews. 2017 May; 18(7): 715-23.
  8. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2014 Aug–Sep; 384(9945): 766–81.
  9. Spoer B, Fullilove R. Obesity: a syndemics perspective. Clin Obes. 2016 Mar; 6(3): 171–4.
  10. Winberg ME, Motlagh MK, Stenkula KG, Holm C, Jones HA. Adiponutrin: a multimeric plasma protein. Biochemical and biophysical research communications. 2014 Apr; 446(4): 1114-9.
  11. Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proceedings of the National Academy of Sciences, 2010 Mar; 107(17): 7892-97.
  12. Pingitore P, Pirazzi C, Mancina RM, Motta BM, Indiveri C, Pujia A, et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids. 2014 Apr; 1841(4): 574-80.
  13. Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Human molecular genetics, 2014 Aug; 23(15): 4077-85.
  14. Kienesberger PC, Oberer M, Lass A, Zechner R. Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functions. Journal of lipid research. 2009; 50 (Suppl): 63-68.
  15. Wu JT, Liu SS, Xie XJ, Liu Q, Xin YN, Xuan SY. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease. Lipids in Health and Disease. 2020 Febr; 19(1): 1-7.
  16. Mantovani A, Chiara Z. PNPLA3 gene and kidney disease. Exploration of Medicine. 2020; 1: 42-50.
  17. Williams B, Mancia G, Spiering W, Rosei EА, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018 Sep; 39(33): 3021-3104.
  18. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2012 Sep; 8(9): 605-19.
  19. Ruixing Y, Jinzhen W, Shangling P, Weixiong L, Dezhai Y, Yuming C. Sex differences in environmental and genetic factors for hypertension. Am J Med. 2008 Sep; 121(9): 811-19.
  20. Ghooshchi G, Masoomian M, Sarafraz Yazdi M, Pour Ramezan M. Evaluation of the lipid profile of hypertensive patients compared to non-hypertensive individuals. Patient Saf Qual Improv. 2014; 2(3): 120-22.
  21. Choudhury KN, Mainuddin AKM, Wahiduzzaman M, Islam SMS. Serum lipid profile and its association with hypertension in Bangladesh. Vasc Health Risk Manag. 2014 Jun; 10: 327–32.
  22. Trépo E, Romeo S, Zucman-Rossi J, Nahon P. PNPLA3 gene in liver diseases. Journal of hepatology. 2016 Aug; 65(2): 399-412.
  23. Bruschi FV, Claudel T, Tardelli M, Caligiuri A, Stulnig TM., Marra F, et al. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology. 2017 Jan; 65(6): 1875-1890.
  24. Johansson LE, Johansson LM, Danielsson P, Norgren S, Johansson, S, Marcus C, et al. Genetic variance in the adiponutrin gene family and childhood obesity. PLoS One, 2009 Apr; 4(4): e5327.
  25. Qadri S, Lallukka‐Brück S, Luukkonen PK, Zhou Y, Gastaldelli A, Orho‐Melander M, et al. The PNPLA3‐I148M variant increases polyunsaturated triglycerides in human adipose tissue. Liver International. 2020 May; 40(9): 2128-38.
  26. Quiroga AD, Lehner R. Pharmacological intervention of liver triacylglycerol lipolysis: The good, the bad and the ugly. Biochemical pharmacology. 2018 Sep; 155: 233-241.